Keyword: Alexion Pharmaceuticals
Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.
Frontier Medicines launches with a biotech vet as CEO; Syntimmune's CEO joins MorphoSys; and Recursion names a Theravance veteran as CSO.
Syntimmune has had a roller-coaster few years, losing CEOs, gaining new ones and then being snapped up by Alexion in 2018 for up to $1.2 billion.
Chugai Pharmaceuticals is shelling out ¥127.3 billion on a new R&D site in Yokohama, where it will combine the work of two research labs in nearby cities.
The deal will see Alexion pay $25 million upfront to work with Zealand on the subcutaneously delivered therapies.
BridgeBio's new spinout launches with a synthetic enzyme replacement from Alexion for an ultrarare genetic disease that causes seizures in infants.
David Thompson has left Azure Biotech to join Inozyme Pharma as chief scientific officer as the company transitions to the clinical stage.
The takeover furthers Alexion’s pipeline rebuild by giving it control of WTX101, a phase 3 treatment for the rare genetic disorder Wilson disease.
Abeona is tapping industry vet Carsten Thiel, Ph.D., for its new leader in the cell and gene therapy space, with an eye to the commercial future.
If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.